| Medical and Health Sciences | 2021-2025 | 989 | NL 25 | 99.77 |
| Nephrology | Lifetime | 46 | NL 3 | 99.64 |
| Genetics | Lifetime | 459 | NL 11 | 98.93 |
| Cardiology and Cardiovascular Medicine | Lifetime | 832 | NL 31 | 98.20 |
| Genetics | 2021-2025 | 71 | NL 3 | 98.42 |
| Nephrology | 2021-2025 | 40 | NL 2 | 98.89 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 431 | NL 18 | 94.47 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 363 | NL 7 | 90.79 |
| Genetic and Kidney Cyst Diseases | Lifetime | 7 | NL 1 | 99.62 |
| Chronic Kidney Disease and Diabetes | Lifetime | 32 | NL 3 | 99.74 |
| Dialysis and Renal Disease Management | Lifetime | 50 | NL 3 | 99.62 |
| Renal Diseases and Glomerulopathies | Lifetime | 87 | NL 4 | 99.37 |
| Blood Pressure and Hypertension Studies | Lifetime | 153 | NL 5 | 99.44 |
| Biomedical Research and Pathophysiology | Lifetime | 39 | NL 2 | 98.56 |
| Renal and Vascular Pathologies | Lifetime | 187 | NL 8 | 98.60 |
| COVID-19 Clinical Research Studies | Lifetime | 521 | NL 14 | 98.01 |
| Renal and related cancers | Lifetime | 617 | NL 22 | 97.24 |
| Diabetes Treatment and Management | Lifetime | 815 | NL 16 | 97.23 |
| Electrolyte and hormonal disorders | Lifetime | 502 | NL 18 | 95.94 |
| COVID-19 and healthcare impacts | Lifetime | 946 | NL 9 | 92.00 |
| Ion Transport and Channel Regulation | Lifetime | 643 | NL 14 | 94.96 |
| Sodium Intake and Health | Lifetime | 336 | NL 9 | 95.00 |
| Acute Kidney Injury Research | Lifetime | 815 | NL 26 | 93.22 |
| Genetic Syndromes and Imprinting | Lifetime | 893 | NL 21 | 92.32 |
| Potassium and Related Disorders | Lifetime | 662 | NL 29 | 89.11 |
| Genetic and Kidney Cyst Diseases | 2021-2025 | 1 | NL 1 | 99.71 |
| Dialysis and Renal Disease Management | 2021-2025 | 44 | NL 4 | 98.80 |
| Biomedical Research and Pathophysiology | 2021-2025 | 4 | NL 1 | 98.15 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 41 | NL 3 | 98.79 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 85 | NL 3 | 98.16 |
| Genetic Syndromes and Imprinting | 2021-2025 | 76 | NL 8 | 90.12 |
| Diabetes Treatment and Management | 2021-2025 | 546 | NL 10 | 94.39 |
| Renal and related cancers | 2021-2025 | 284 | NL 13 | 91.77 |
| Parathyroid Disorders and Treatments | 2021-2025 | 688 | NL 23 | 83.42 |
| Hormonal Regulation and Hypertension | 2021-2025 | 853 | NL 29 | 80.64 |
| Healthcare cost, quality, practices | 2021-2025 | 775 | NL 46 | 72.48 |
| Electrolyte and hormonal disorders | 2021-2025 | 738 | NL 33 | 64.36 |
| Magnesium in Health and Disease | 2021-2025 | 415 | NL 20 | 53.58 |
| Ion Transport and Channel Regulation | 2021-2025 | 866 | NL 14 | 48.90 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 747 | NL 7 | 42.81 |
